Trametinib Shows Promise for Children with Relapsed or Refractory JMML

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years, according to results published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR).

Read more: https://www.aacr.org/about-the-aacr/newsroom/news-releases/trametinib-shows-promise-for-children-with-relapsed-or-refractory-jmml/